Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2023
Acutus Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
2210 Faraday Ave., Suite 100
Carlsbad, CA
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (442) 232-6080
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001AFIBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On August 7, 2023, the Company issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of this press release is attached as Exhibit 99.1 to this current report on Form 8-K.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01.    Financial Statements and Exhibits.
104.0Cover Page Interactive Data File (embedded within the Inline XBRL document)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Acutus Medical, Inc.
Date: August 7, 2023By:
/s/ David Roman
David Roman
President and Chief Executive Officer
Press Release
Exhibit 99.1
Acutus Medical Reports Second Quarter 2023 Financial Results
CARLSBAD, Calif., August 7, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023.
Recent Highlights:
Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital sales
Quarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022
Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabilities and procedure workflow
Significant improvements in non-GAAP gross margin and cash burn resulting from disciplined focus on operational excellence

“Our second quarter performance reflects significant progress on our key strategic initiatives to return our business to growth while driving further operational improvement. During the second quarter of 2023, we achieved record procedure volumes, as focused commercial execution, pull through from the AcQMap 8.5 software launch, and the positive results from the RECOVER AF study supported accelerated AcQMap adoption,” said David Roman, President & CEO of Acutus Medical. “The strategic actions we have successfully undertaken over the past year, along with our team’s crisp execution, are driving momentum in our business and enabling our mission to create a new paradigm for the diagnosis and treatment of complex cardiac arrhythmias.”
Second Quarter 2023 Financial Results
Revenue was $5.3 million for the second quarter of 2023, an increase of 30% compared to $4.1 million for the second quarter of 2022. The improvement over the same quarter last year was primarily driven by disposables sales, higher capital conversions, increases in service, rent and other revenue, and sales through the Company’s distribution agreement with Medtronic.
Non-GAAP gross margin was negative 49% for the second quarter of 2023 compared to negative 129% for the same quarter last year. The improvement was driven by higher production volumes, improved product and geographic mix, lower manufacturing variances, and a reduced manufacturing overhead structure.
Non-GAAP operating expenses were $14.5 million for the second quarter of 2023 compared with $19.7 million in the same quarter last year. The decrease in operating expenses resulted from the Company’s restructuring actions in the first half of 2022, reduced discretionary spend, and the reprioritization of certain research and development programs.
Non-GAAP net loss for the second quarter of 2023 was $17.6 million, or $0.60 per share on a weighted average basic and diluted outstanding share count of 29.0 million, compared to non-GAAP net loss of $26.2 million, or $0.93 per share on a weighted average basic and diluted outstanding share count of 28.3 million, for the second quarter of 2022.
Cash, cash equivalents, marketable securities and restricted cash were $61.5 million as of June 30, 2023.
2023 Outlook
The company now expects full year 2023 revenue to be in a range from $20.0-$22.0 million.
Non-GAAP Financial Measures
This press release includes references to non-GAAP net loss and non-GAAP basic and diluted net loss per share, which are non-GAAP financial measures, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important indicators of its operating performance because they exclude items that are
primarily non-cash accounting line items unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as Acutus calculates them, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. Non-GAAP net loss is defined as net loss before income taxes, adjusted for stock-based compensation, amortization of acquisition-related intangibles, employee retention credit, goodwill impairment, restructuring charges, changes in the fair value of contingent consideration, gain on sale of business, loss on debt extinguishment and change in fair value of warrant liability and other adjustments. To the extent such non-GAAP financial measures are used in the future, the Company expects to calculate them using a consistent method from period to period. A reconciliation of the most directly comparable GAAP financial measure to the non-GAAP financial measure has been provided under the heading “Reconciliation of GAAP Results to Non-GAAP Results” in the financial statement tables attached to this press release.
Webcast and Conference Call Information
Acutus will host a conference call to discuss the second quarter 2023 financial results after market close on Monday, August 7, 2023 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To access the live call via telephone, please register in advance using the link: Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed at
About Acutus
Acutus is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.
Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of its products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase the Company’s systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the impact of the coronavirus (COVID-19) pandemic and Acutus’ response to it and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Media Contact:
Caroline Corner
Rhiannon Pickus
Westwicke ICR
Acutus Medical, Inc.
D: 415-202-5678M: 442-232-6094
Condensed Consolidated Balance Sheets
(in thousands, except per share amounts)
June 30, 2023December 31, 2022
Current assets:
Cash and cash equivalents$23,055 $25,584 
Marketable securities, short-term31,461 44,863 
Restricted cash, short-term7,002 5,764 
Accounts receivable7,670 21,085 
Inventory15,671 13,327 
Employer retention credit receivable— 4,703 
Prepaid expenses and other current assets2,444 2,541 
Total current assets87,303 117,867 
Property and equipment, net7,245 9,221 
Right-of-use asset, net3,533 3,872 
Intangible assets, net1,483 1,583 
Other assets731 897 
Total assets$100,295 $133,440 
Current liabilities:
Accounts payable$5,492 $4,721 
Accrued liabilities9,759 9,686 
Contingent consideration, short-term— 1,800 
Operating lease liabilities, short-term466 319 
Warrant liability2,504 3,346 
Total current liabilities18,221 19,872 
Operating lease liabilities, long-term3,679 4,103 
Long-term debt34,634 34,434 
Other long-term liabilities20 12 
Total liabilities56,554 58,421 
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of June 30, 2023 and December 31, 2022— — 
Common stock, $0.001 par value; 260,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 29,206,570 and 28,554,656 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively29 29 
Additional paid-in capital597,578 594,173 
Accumulated deficit(552,975)(518,314)
Accumulated other comprehensive loss(891)(869)
Total stockholders' equity 43,741 75,019 
Total liabilities and stockholders' equity$100,295 $133,440
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
Revenue$5,289 $4,076 $9,458 $7,757 
Cost of products sold8,063 9,697 14,852 16,638 
Gross profit(2,774)(5,621)(5,394)(8,881)
Operating expenses (income):
Research and development6,799 7,935 12,916 15,938 
Selling, general and administrative9,284 14,143 18,849 28,528 
Goodwill impairment— — — 12,026 
Restructuring463 — 475 949 
Change in fair value of contingent consideration(77)948 123 955 
Gain on sale of business(2,072)(43,575)(3,279)(43,575)
Total operating expenses (income)14,397 (20,549)29,084 14,821 
Income (loss) from operations(17,171)14,928 (34,478)(23,702)
Other income (expense):
Loss on debt extinguishment— (7,947)— (7,947)
Change in fair value of warrant liability (604)— 842 — 
Interest income824 27 1,676 51 
Interest expense(1,395)(1,290)(2,701)(2,701)
Total other expense, net(1,175)(9,210)(183)(10,597)
(Loss) income before income taxes(18,346)5,718 (34,661)(34,299)
Income tax benefit— — — — 
Net (loss) income$(18,346)$5,718 $(34,661)$(34,299)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities(8)18 (39)
Foreign currency translation adjustment(85)(387)(26)(553)
Comprehensive income (loss)$(18,439)$5,349 $(34,683)$(34,891)
Basic net income (loss) per common share$(0.63)$0.16 $(1.20)$(1.22)
Diluted net income (loss) per common share$(0.63)$0.16 $(1.20)$(1.22)
Basic weighted average shares outstanding29,039,732 28,339,362 28,902,808 28,229,338 
Diluted weighted average shares outstanding29,039,732 28,349,429 28,902,808 28,229,338
Condensed Consolidated Statements of Cash Flows
(in thousands)
Six Months Ended June 30,
Cash flows from operating activities
Net loss$(34,661)$(34,299)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense2,473 3,145 
AcQMap Systems converted to sales238 110 
Sales-type lease gain(310)(57)
Amortization of intangible assets100 320 
Non-cash stock-based compensation expense3,639 5,613 
(Accretion of discounts) amortization of premiums on marketable securities, net(1,037)264 
Amortization of debt issuance cost212 641 
Amortization of operating lease right-of-use assets339 321 
Loss on debt extinguishment— 7,947 
Goodwill impairment— 12,026 
Gain on sale of business, net(3,279)(43,575)
Direct costs paid related to sale of business— (2,488)
Change in fair value of warrant liability(842)— 
Loss on disposal of property and equipment277 — 
Change in fair value of contingent consideration123 955 
Changes in operating assets and liabilities:
Accounts receivable(204)1,037 
Employer retention credit receivable4,703 — 
Prepaid expenses and other current assets432 (3,592)
Other assets452 223 
Accounts payable824 236 
Accrued liabilities(1,963)(386)
Operating lease liabilities(277)(203)
Other long-term liabilities(45)
Net cash used in operating activities(31,097)(50,706)
Cash flows from investing activities
Proceeds from sale of business17,000 50,000 
Purchases of available-for-sale marketable securities(33,880)— 
Sales of available-for-sale marketable securities— 13,099 
Maturities of available-for-sale marketable securities48,250 27,787 
Purchases of property and equipment(984)(1,718)
Net cash provided by investing activities30,386 89,168 
Cash flows from financing activities
Repayment of debt— (44,550)
Penalty fees paid for early prepayment of debt— (1,074)
Borrowing under new debt— 35,000 
Payment of debt issuance costs— (624)
Proceeds from the exercise of stock options66 
Repurchase of common shares to pay employee withholding taxes(263)(45)
Proceeds from employee stock purchase plan25 182 
Payment of contingent consideration— (598)
Net cash used in financing activities(234)(11,643)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(346)(323)
Net change in cash, cash equivalents and restricted cash(1,291)26,496 
Cash, cash equivalents and restricted cash, at the beginning of the period31,348 24,221 
Cash, cash equivalents and restricted cash, at the end of the period$30,057 $50,717 
Supplemental disclosure of cash flow information:
Cash paid for interest$2,458 $2,073
Six Months Ended June 30,
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business$3,381 $— 
Change in unrealized (gain) loss on marketable securities$(4)$39 
Change in unpaid purchases of property and equipment$(54)$42 
Contingent consideration escrow release$— $157 
Net book value on AcQMap system sales-type leases$238 $110 
Amount of debt proceeds allocated to warrant liability$— $3,379 
Unpaid transaction costs from sale of business$— $429 
Unpaid debt issuance costs$— $177
Reconciliation of GAAP Results to Non-GAAP Results
(in thousands)
Three Months Ended June 30, 2023Cost of Products SoldResearch and DevelopmentSelling, General and AdministrativeLoss from OperationsOther Expense, NetNet LossBasic and Diluted EPS
Reported$8,063 $6,799 $9,284 $(17,171)$(1,175)$(18,346)$(0.63)
Amortization of acquired intangibles(50)— — 50 — 50 0.00
Stock-based compensation(153)(336)(1,245)1,734 — 1,734 0.06
Restructuring charges— — — 463 — 463 0.02
Change in fair value of warrant liability— — — — 604 604 0.02
Change in fair value of contingent consideration— — — (77)— (77)0.00
 Gain on sale of business — — — (2,072)— (2,072)(0.07)
Adjusted$7,860 $6,463 $8,039 $(17,073)$(571)$(17,644)$(0.60)
Three Months Ended June 30, 2022Cost of Products SoldResearch and DevelopmentSelling, General and AdministrativeIncome (Loss) from OperationsOther Expense, NetNet Income (Loss)Net income allocated to common stockholdersBasic and Diluted EPS
Reported$9,697 $7,935 $14,143 $14,928 $(9,210)$5,718 $4,521 $0.16
Amortization of acquired intangibles(155)— (5)160 — 160 160 0.01
Stock-based compensation(225)(554)(1,802)2,581 — 2,581 2,581 0.09
Change in fair value of contingent consideration— — — 948 — 948 948 0.03
Gain on sale of business— — — (43,575)— (43,575)(43,575)(1.54)
Loss on debt extinguishment— — — — 7,947 7,947 7,947 0.28
Net income allocated to participating securities— — — — — — 1,197 0.04
Adjusted$9,317 $7,381 $12,336 $(24,958)$(1,263)$(26,221)$(26,221)$(0.93)
Key Business Metrics
Installed Base and Procedure Volumes
The total installed base which includes AcQMap Systems as of June 30, 2023 and 2022 are as follows:
As of June 30,
U.S.27 37 
Outside the U.S.51 38 
Total Acutus net system placements78 75 

Procedure volumes for the three and six months ended June 30, 2023 and 2022 are as follows:
Three Months EndedSix Months Ended
June 30,June 30,
Procedure volumes5844811,035 948
The following table sets forth the Company’s revenue for disposables, systems and service/other for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months EndedSix Months Ended
June 30,June 30,
Disposables$3,914 $3,334 $7,340 $6,545 
Systems691 346 691 346 
Service / other684 396 1,427 866 
Total revenue$5,289 $4,076 $9,458 $7,757 
The following table presents revenue by geographic location for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months EndedSix Months Ended
June 30,June 30,
United States$3,125 $2,037 $5,373 $4,060 
Outside the United States2,164 2,039 4,085 3,697 
Total revenue$5,289 $4,076 $9,458 $7,757